Aspirin, Tumor Mutations, & Colorectal Cancer Survival | News Brief

Among patients with mutated-PIK3CA colorectal cancer, regular aspirin use after their diagnosis appears to increase survival. The investigators noted, however, that survival was unchanged for those with wild-type PIK3CA colorectal cancer.

Abstract: New England Journal of Medicine, October 25, 2012.


From our CME partner, AKH Inc.

CME: On the Spot Oncology
CME Credit: .25 hour activities

While several aspects of therapy for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have remained unchanged for several decades, new therapeutic options have emerged within the past 5 years, particularly targeted agents. These agents represent a new era for treatment of GEP-NETs, but also create a key area of educational need, as the new data challenge the current paradigm of patient treatment. These activities review the novel treatment choices for improving care in patients diagnosed with GEP-NETs.

eMedia - Oncology




Physician's Weekly for Current Medical News, Events & Issues